The 766,000 Shares in Astrazeneca PLC (AZN) Acquired by OLD Republic International Corp, Report finds

The 766,000 Shares in Astrazeneca PLC (AZN) Acquired by OLD Republic International Corp, Report finds

A number of other institutional investors have also modified their holdings of the stock. Capital International Investors increased its position in shares of Astrazeneca PLC by 0.6% in the third quarter. Capital International Investors now owns 20,600,179 shares of the company’s stock worth $676,922,000 after buying an additional 126,700 shares during the period. Primecap Management Co. CA increased its position in shares of Astrazeneca PLC by 17.4% in the second quarter. Primecap Management Co. CA now owns 15,365,950 shares of the company’s stock worth $463,898,000 after buying an additional 2,281,675 shares during the period. BlackRock Investment Management LLC increased its position in shares of Astrazeneca PLC by 12.1% in the third quarter. BlackRock Investment Management LLC now owns 8,079,111 shares of the company’s stock worth $265,480,000 after buying an additional 872,075 shares during the period. Epoch Investment Partners Inc. increased its position in shares of Astrazeneca PLC by 1.8% in the third quarter. Epoch Investment Partners Inc. now owns 7,935,629 shares of the company’s stock worth $260,765,000 after buying an additional 137,571 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of Astrazeneca PLC by 57.5% in the third quarter. Wells Fargo & Company MN now owns 3,365,503 shares of the company’s stock worth $110,589,000 after buying an additional 1,228,331 shares during the period. 12.90% of the stock is currently owned by hedge funds and other institutional investors.

OLD Republic International Corp purchased a new stake in shares of Astrazeneca PLC (NYSE:AZN) during the third quarter, Holdings Channel reports. The firm purchased 766,000 shares of the company’s stock, valued at approximately $24,577,000.

Astrazeneca PLC (NYSE:AZN) opened at 29.53 on Monday. The company has a market cap of $74.71 billion, a price-to-earnings ratio of 21.40 and a beta of 0.77. The stock has a 50 day moving average price of $27.88 and a 200-day moving average price of $30.06. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.04.

Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, February 2nd. The company reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.62. The company had revenue of $5.59 billion for the quarter, compared to analyst estimates of $5.43 billion. Astrazeneca PLC had a return on equity of 34.30% and a net margin of 15.21%. The firm’s quarterly revenue was down 12.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.94 earnings per share. On average, equities research analysts forecast that Astrazeneca PLC will post $1.82 EPS for the current year.

The company also recently announced a semiannual dividend, which will be paid on Monday, March 20th. Shareholders of record on Friday, February 17th will be given a $0.95 dividend. This represents a yield of 6.81%. The ex-dividend date is Wednesday, February 15th. Astrazeneca PLC’s payout ratio is 49.64%.

Several research analysts have recently weighed in on AZN shares. Vetr upgraded Astrazeneca PLC from a “buy” rating to a “strong-buy” rating and set a $30.35 price target for the company in a research note on Monday, January 23rd. Cantor Fitzgerald reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, October 28th. Liberum Capital upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Friday, November 25th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Astrazeneca PLC in a research note on Wednesday, November 2nd. Finally, Deutsche Bank AG reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $34.44.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Related posts

Leave a Comment